Sentiment-Signal
19,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Day One Biopharmaceuticals, Inc. |
|---|---|
| Ticker | DAWN |
| CIK | 0001845337 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,22 Mrd. USD |
| Beta | -1,75 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 158,182,000 | -107,322,000 | -1.04 | 507,827,000 | 441,162,000 |
| 2025-09-30 | 10-Q | 39,795,000 | -19,726,000 | -0.19 | 513,780,000 | 450,868,000 |
| 2025-06-30 | 10-Q | 33,908,000 | -30,322,000 | -0.29 | 519,037,000 | 460,834,000 |
| 2025-03-31 | 10-Q | 30,761,000 | -35,996,000 | -0.35 | 534,356,000 | 479,512,000 |
| 2024-12-31 | 10-K | 131,161,000 | -95,496,000 | -1.02 | 582,788,000 | 502,751,000 |
| 2024-09-30 | 10-Q | 93,761,000 | 37,037,000 | 0.38 | 600,807,000 | 555,463,000 |
| 2024-06-30 | 10-Q | 8,192,000 | -4,407,000 | -0.05 | 400,437,000 | 306,731,000 |
| 2024-03-31 | 10-Q | 0 | -62,412,000 | -0.72 | 326,645,000 | 296,806,000 |
| 2023-12-31 | 10-K | 0 | -188,917,000 | -2.37 | 376,048,000 | 346,540,000 |
| 2023-09-30 | 10-Q | 0 | -46,150,000 | -0.54 | 414,179,000 | 389,627,000 |
| 2023-06-30 | 10-Q | -45,863,000 | -0.61 | 450,756,000 | 426,054,000 | |
| 2023-03-31 | 10-Q | -42,393,000 | -0.59 | 323,563,000 | 300,415,000 | |
| 2022-12-31 | 10-K | 0 | -142,181,000 | -2.17 | 349,062,000 | 332,039,000 |
| 2021-03-31 | 10-Q | -15,182,000 | -68,849,000 | |||
| 2020-12-31 | 10-K | -40,507,000 | -7.33 | 45,661,000 | -54,205,000 | |
| 2020-03-31 | 10-Q | -1,535,000 | -12,149,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | VASCONCELLES MICHAEL | Officer, Head of Research and Dev. | Open Market Sale | -2,728 | 11.60 | -31,647.26 | -44,8% | |
| 2026-02-17 | York Charles N II | Officer, COO and CFO | Open Market Sale | -6,065 | 11.60 | -70,359.46 | -99,6% | |
| 2026-02-17 | Bender Jeremy | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -15,459 | 11.60 | -179,338.31 | -253,8% | |
| 2026-02-17 | Dubow Adam | Officer, Gen Counsel & Secretary | Open Market Sale | -6,395 | 11.60 | -74,187.76 | -105,0% | |
| 2026-02-17 | Merendino Lauren | Officer, Chief Commercial Officer | Open Market Sale | -5,814 | 11.60 | -67,447.63 | -95,4% | |
| 2025-11-17 | Bender Jeremy | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -15,894 | 8.91 | -141,690.24 | -200,5% | |
| 2025-11-17 | Dubow Adam | Officer, Gen Counsel & Secretary | Open Market Sale | -4,319 | 8.91 | -38,502.59 | -54,5% | |
| 2025-11-17 | York Charles N II | Officer, COO and CFO | Open Market Sale | -4,062 | 8.91 | -36,211.51 | -51,2% | |
| 2025-11-17 | Merendino Lauren | Officer, Chief Commercial Officer | Open Market Sale | -3,726 | 8.91 | -33,216.17 | -47,0% | |
| 2025-08-18 | Bender Jeremy | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -16,058 | 6.77 | -108,666.09 | -153,8% | |
| 2025-08-18 | Merendino Lauren | Officer, Chief Commercial Officer | Open Market Sale | -3,766 | 6.77 | -25,484.90 | -36,1% | |
| 2025-05-16 | Merendino Lauren | Officer, Chief Commercial Officer | Open Market Sale | -3,927 | 6.26 | -24,574.77 | -34,8% | |
| 2025-05-16 | Bender Jeremy | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -13,964 | 6.26 | -87,385.32 | -123,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.